Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Gynecologic Oncology|April 6, 2020
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaL R Duska, G R Petroni, N Varhegyi, et al.
Gynecologic Oncology|June 30, 2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimenU A Matulonis, S Campos, C N Krasner, et al.
Gynecologic Oncology|September 23, 2017
A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancerG Rustin, I Vergote, J P Micha, et al.
Gynecologic Oncology|March 1, 1996
Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III diseaseB A Goff, R Sainz de la Cuesta, H G Muntz, et al.
Gynecologic Oncology|May 1, 2022
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometriumC G Jackson, K N Moore, L Cantrell, et al.
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Pageof 5